Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that
include medulloblastoma and high grade glioma, that are no longing responding to standard
therapies. The drug mebendazole is an oral drug in a chewable 500 mg orange flavored tablet.
It is already approved to treat parasitic infections. The purpose of this study is to
determine the safety and side effects for increasing doses of mebendazole, followed by the
treatment of an additional 12 patients at the best tolerated dose.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins